A018680 Stock Overview
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Seoul Pharma Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,335.00 |
| 52 Week High | ₩4,565.00 |
| 52 Week Low | ₩3,230.00 |
| Beta | 0 |
| 1 Month Change | -5.79% |
| 3 Month Change | -5.26% |
| 1 Year Change | -20.12% |
| 3 Year Change | -63.59% |
| 5 Year Change | -57.78% |
| Change since IPO | -48.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| A018680 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.6% | 3.9% | 0.5% |
| 1Y | -20.1% | 8.3% | 4.7% |
Return vs Industry: A018680 underperformed the KR Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: A018680 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
| A018680 volatility | |
|---|---|
| A018680 Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A018680 has not had significant price volatility in the past 3 months.
Volatility Over Time: A018680's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | n/a | DongHyun Yoon | www.seoulpharma.com |
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer’ disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH
Seoul Pharma Co., Ltd Fundamentals Summary
| A018680 fundamental statistics | |
|---|---|
| Market cap | ₩38.88b |
| Earnings (TTM) | ₩1.05b |
| Revenue (TTM) | ₩42.28b |
0.0x
P/E Ratio0.0x
P/S RatioIs A018680 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A018680 income statement (TTM) | |
|---|---|
| Revenue | ₩42.28b |
| Cost of Revenue | ₩20.58b |
| Gross Profit | ₩21.70b |
| Other Expenses | ₩20.65b |
| Earnings | ₩1.05b |
Last Reported Earnings
Sep 30, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A018680 perform over the long term?
See historical performance and comparison